Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Unternehmen & Branche
| Name | Context Therapeutics Inc. |
|---|---|
| Ticker | CNTX |
| CIK | 0001842952 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 215,0 Mio. USD |
| Beta | 1,83 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -36,123,615 | -0.38 | 68,493,768 | 60,473,727 | |
| 2025-09-30 | 10-Q | -9,693,237 | -0.10 | 79,231,160 | 73,174,166 | |
| 2025-06-30 | 10-Q | -8,827,510 | -0.09 | 87,152,101 | 82,544,322 | |
| 2025-03-31 | 10-Q | -4,577,261 | -0.05 | 92,965,483 | 90,982,718 | |
| 2024-12-31 | 10-K | -26,725,104 | -0.46 | 98,126,759 | 95,266,262 | |
| 2024-09-30 | 10-Q | -17,459,893 | -0.22 | 86,329,849 | 83,857,617 | |
| 2024-06-30 | 10-Q | -2,254,506 | -0.04 | 102,708,853 | 101,104,508 | |
| 2024-03-31 | 10-Q | -3,667,797 | -0.23 | 11,051,652 | 8,443,230 | |
| 2023-12-31 | 10-K | -23,964,211 | -1.50 | 16,062,735 | 11,871,020 | |
| 2023-09-30 | 10-Q | -5,874,686 | -0.37 | 22,988,623 | 18,384,855 | |
| 2023-06-30 | 10-Q | -5,011,321 | -0.31 | 27,762,042 | 24,004,592 | |
| 2023-03-31 | 10-Q | -6,308,318 | -0.40 | 31,966,182 | 28,732,810 | |
| 2022-12-31 | 10-K | -14,835,939 | -0.93 | 37,965,943 | 34,758,366 | |
| 2022-09-30 | 10-Q | -3,854,310 | -0.24 | 42,083,021 | 38,071,510 | |
| 2022-06-30 | 10-Q | -3,986,511 | -0.25 | 44,696,793 | 41,649,299 | |
| 2022-03-31 | 10-Q | -3,438,337 | -0.22 | 47,032,812 | 45,394,486 | |
| 2021-12-31 | 10-K | -10,456,870 | -3.69 | 51,305,750 | 48,272,335 | |
| 2021-09-30 | 10-Q | -1,442,792 | -4.00 | 2,259,304 | -23,213,933 | |
| 2021-06-30 | 10-Q | -5,030,164 | -14.18 | -22,304,859 | ||
| 2021-03-31 | 10-Q | -892,049 | -2.55 | -17,478,072 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-06-09 | Lehr Martin A. | Director, Officer, Chief Executive Officer | Open Market Purchase | 100,000 | 0.70 | 70,080.00 | +196,3% | |
| 2025-06-06 | Levit Alex C. | Officer, Chief Legal Officer, Corp. Sec | Open Market Purchase | 20,000 | 0.58 | 11,520.00 | +32,3% | |
| 2025-06-06 | Minai-Azary Jennifer Lynn | Officer, Chief Financial Officer | Open Market Purchase | 40,010 | 0.64 | 25,486.37 | +71,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.